Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.

Bonneau C, Paintaud G, Trédan O, Dubot C, Desvignes C, Dieras V, Taillibert S, Tresca P, Turbiez I, Li J, Passot C, Mefti F, Mouret-Fourme E, Le Rhun E, Gutierrez M.

Eur J Cancer. 2018 Apr 7;95:75-84. doi: 10.1016/j.ejca.2018.02.032. [Epub ahead of print]

PMID:
29635147
2.

Autocrine Adenosine regulates tumor polyfunctional CD73+CD4+ effector T cells devoid of immune checkpoints.

Gourdin N, Bossennec M, Rodriguez C, Vigano S, Machon C, Jandus C, Bauché D, Faget J, Durand I, Chopin N, Tredan O, Marie JC, Dubois B, Guitton J, Romero P, Caux C, Ménétrier-Caux C.

Cancer Res. 2018 Mar 20. pii: canres.2405.2017. doi: 10.1158/0008-5472.CAN-17-2405. [Epub ahead of print]

PMID:
29559470
3.

Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients.

de Ciantis M, Faure C, Heudel PE, Tredan O, Rousset-Jablonski C.

J Gynecol Obstet Hum Reprod. 2018 Mar 3. pii: S2468-7847(18)30006-0. doi: 10.1016/j.jogoh.2018.03.002. [Epub ahead of print]

PMID:
29510273
4.

Percutaneous cryoablation of breast tumours in patients with stable metastatic breast cancer: safety, feasibility and efficacy.

Beji H, Pilleul F, Picard R, Tredan O, Bouhamama A, Peix M, Mavrovi E, Mastier C.

Br J Radiol. 2018 Feb;91(1083):20170500. doi: 10.1259/bjr.20170500. Epub 2018 Jan 12.

PMID:
29243490
5.

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.

Jobard E, Trédan O, Bachelot T, Vigneron AM, Aït-Oukhatar CM, Arnedos M, Rios M, Bonneterre J, Diéras V, Jimenez M, Merlin JL, Campone M, Elena-Herrmann B.

Oncotarget. 2017 Jun 28;8(48):83570-83584. doi: 10.18632/oncotarget.18784. eCollection 2017 Oct 13.

6.

Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer.

Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Derbel O, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger S, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I.

Clin Cancer Res. 2018 Jan 15;24(2):326-333. doi: 10.1158/1078-0432.CCR-17-2136. Epub 2017 Oct 30.

PMID:
29084914
7.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A.

J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.

PMID:
28968163
8.

Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.

Bernichon E, Vallard A, Wang Q, Attignon V, Pissaloux D, Bachelot T, Heudel PE, Ray-Coquard I, Bonnet E, de la Fouchardière A, Faure C, Chopin N, Beurrier F, Racadot S, Sunyach MP, Rancoule C, Perol D, Corset V, Agrapart V, Tinquaut F, Blay JY, Magné N, Trédan O.

Ann Oncol. 2017 Nov 1;28(11):2773-2779. doi: 10.1093/annonc/mdx488.

PMID:
28945826
9.

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.

Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, Baselga J.

Breast Cancer Res Treat. 2017 Oct;165(3):601-609. doi: 10.1007/s10549-017-4375-5. Epub 2017 Jul 5.

PMID:
28681171
10.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, E Heudel P, Cassier P, Chabaud S, Croughs T, Dupont P, C Cadore A, Clapisson G, Delgado A, Bardin-Dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2018 Feb 1;29(2):523. doi: 10.1093/annonc/mdx058. No abstract available.

PMID:
28368453
11.

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.

Rochefort P, Chabaud S, Pierga JY, Tredan O, Brain E, Bidard FC, Schiffler C, Polena H, Khalil-Mgharbel A, Vilgrain I, Bachelot T.

Br J Cancer. 2017 Jan;116(3):356-361. doi: 10.1038/bjc.2016.427. Epub 2017 Jan 5.

12.

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C.

Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666.

PMID:
27993804
13.

A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies.

Jobard E, Trédan O, Postoly D, André F, Martin AL, Elena-Herrmann B, Boyault S.

Int J Mol Sci. 2016 Dec 5;17(12). pii: E2035.

14.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

15.

PI3K targeting in breast cancer: the end of the beginning?

Bachelot T, Campone M, Tredan O.

Lancet Oncol. 2016 Jun;17(6):696-697. doi: 10.1016/S1470-2045(16)00148-0. Epub 2016 May 4. No abstract available.

PMID:
27155742
16.

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay.

Verronèse E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, Ray-Coquard I, Bachelot T, N'Kodia A, Bardin-Dit-Courageot C, Rigal C, Pérol D, Caux C, Ménétrier-Caux C.

Oncoimmunology. 2015 Nov 10;5(3):e1100791. eCollection 2016 Mar.

17.

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A.

Ann Oncol. 2016 May;27(5):812-8. doi: 10.1093/annonc/mdw067. Epub 2016 Feb 18.

PMID:
27052658
18.

Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study.

Selle F, Emile G, Pautier P, Asmane I, Soares DG, Khalil A, Alexandre J, Lhommé C, Ray-Coquard I, Lotz JP, Goldwasser F, Tazi Y, Heudel P, Pujade-Lauraine E, Gouy S, Tredan O, Barbaza MO, Ady-Vago N, Dubot C.

Oncol Lett. 2016 Mar;11(3):1859-1865. Epub 2016 Jan 26.

19.

Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies.

Cornet S, Mathé D, Chettab K, Evesque A, Matera EL, Trédan O, Dumontet C.

Mol Cancer Ther. 2016 Jun;15(6):1238-47. doi: 10.1158/1535-7163.MCT-15-0759. Epub 2016 Mar 17.

20.

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.

Trédan O, Follana P, Moullet I, Cropet C, Trager-Maury S, Dauba J, Lavau-Denes S, Diéras V, Béal-Ardisson D, Gouttebel M, Orfeuvre H, Stefani L, Jouannaud C, Bürki F, Petit T, Guardiola E, Becuwe C, Blot E, Pujade-Lauraine E, Bachelot T.

Ann Oncol. 2016 Jun;27(6):1020-9. doi: 10.1093/annonc/mdw077. Epub 2016 Feb 24.

PMID:
26916095
21.

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.

Jobard E, Blanc E, Négrier S, Escudier B, Gravis G, Chevreau C, Elena-Herrmann B, Trédan O.

Br J Cancer. 2015 Oct 20;113(8):1148-57. doi: 10.1038/bjc.2015.322. Epub 2015 Sep 15.

22.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bièche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X; SHIVA investigators.

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

PMID:
26342236
23.

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY.

Oncotarget. 2015 Sep 22;6(28):26388-99. doi: 10.18632/oncotarget.4557.

24.

[Axillary lymph node metastases with an occult breast: About 16 cases from a cohort of 7770 patients].

Couder F, Schmitt C, Treilleux I, Tredan O, Faure C, Carrabin N, Beurrier F, Chopin N.

Gynecol Obstet Fertil. 2015 Sep;43(9):588-92. doi: 10.1016/j.gyobfe.2015.06.010. Epub 2015 Aug 6. French.

PMID:
26257298
25.

[Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].

Vanacker H, Bally O, Kassem L, Tredan O, Heudel P, Bachelot T.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S47-52. doi: 10.1016/S0007-4551(15)31217-0. Review. French.

PMID:
26118876
26.

[Quinze questions importantes à se poser en oncologie en 2015].

Blay JY, Tredan O, Ray-Coquard I, Rivoire M, Mehlen P, Puisieux A, Bachelot T.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S22-6. doi: 10.1016/S0007-4551(15)31214-5. Review. French.

PMID:
26118872
27.

Role of JMJD6 in Breast Tumourigenesis.

Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Trédan O, Chabaud S, Treilleux I, Corbo L, Le Romancer M.

PLoS One. 2015 May 7;10(5):e0126181. doi: 10.1371/journal.pone.0126181. eCollection 2015.

28.

[Metastatic screening before adjuvant chemotherapy in breast cancer].

Thonnon C, Faure C, Chopin N, Beurrier F, Ho Quoc C, Tredan O, Carrabin N.

Bull Cancer. 2015 May;102(5):411-6. doi: 10.1016/j.bulcan.2015.02.018. Epub 2015 Apr 27. French.

PMID:
25931010
29.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2015 Jul;26(7):1353-62. doi: 10.1093/annonc/mdv173. Epub 2015 Apr 7.

PMID:
25851629
30.

[New therapeutical strategies in metastatic hormone-dependent breast cancer].

Vilquin P, Cohen P, Maudelonde T, Tredan O, Treilleux I, Bachelot T, Heudel PE.

Bull Cancer. 2015 Apr;102(4):367-80. doi: 10.1016/j.bulcan.2015.02.013. Epub 2015 Mar 21. Review. French.

31.

Therogenetics: transferring GWAS technology to the clinic.

Cox DG, Heudel PE, Trédan O, Bachelot T.

Mutagenesis. 2015 Mar;30(2):213-5. doi: 10.1093/mutage/geu060. Review.

PMID:
25688114
32.

Survivorship in untreated breast cancer patients.

Galmarini CM, Tredan O, Galmarini FC.

Med Oncol. 2015 Feb;32(2):466. doi: 10.1007/s12032-014-0466-x. Epub 2015 Jan 15. Review.

PMID:
25588926
33.

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.

Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D.

Ann Oncol. 2015 Feb;26(2):325-32. doi: 10.1093/annonc/mdu551. Epub 2014 Dec 1.

34.

Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors.

Perrier L, Kembou NS, Rascle P, Bui B, Morelle M, Ranchère VD, Terrier P, Neuville A, Decouvelaere AV, Le Cesne A, Gomez F, de la Fouchardière C, Meeus P, Trédan O, Pérol M, Fayette J, Neidhardt EM, Biron P, Boyle HJ, Marec BP, Farsi F, Ducimetière F, Blay JY, Ray CI, Coindre JM.

Value Health. 2014 Nov;17(7):A624. doi: 10.1016/j.jval.2014.08.2219. Epub 2014 Oct 26. No abstract available.

35.

Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.

Trédan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, Aloe A, Roché H.

Clin Breast Cancer. 2015 Feb;15(1):8-15. doi: 10.1016/j.clbc.2014.07.007. Epub 2014 Aug 15.

PMID:
25218708
36.

Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis.

Foucaut AM, Berthouze SE, Touillaud M, Morelle M, Bourne-Branchu V, Kempf-Lépine AS, Carretier J, Pérol D, Trédan O, Bachmann P, Fervers B.

Cancer Nurs. 2015 Jul-Aug;38(4):E1-9. doi: 10.1097/NCC.0000000000000187.

PMID:
25207592
37.

Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.

Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P.

Target Oncol. 2015 Jun;10(2):189-98. doi: 10.1007/s11523-014-0334-9. Epub 2014 Sep 5. Review.

PMID:
25185646
38.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Trédan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F.

Med Oncol. 2014 Aug;31(8):76. doi: 10.1007/s12032-014-0076-7. Epub 2014 Jun 26.

PMID:
24965536
39.

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.

Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F.

Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183. Epub 2014 May 14.

PMID:
24827135
40.

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M.

Br J Cancer. 2014 Jul 8;111(1):17-24. doi: 10.1038/bjc.2014.211. Epub 2014 Apr 24.

41.

[Spontaneous regression of breast cancer after biopsy. About two cases].

Maillet L, Chopin N, Treilleux I, Bachelot T, Tredan O, Faure C, Caux C, Beurrier F.

Gynecol Obstet Fertil. 2014 Apr;42(4):269-72. doi: 10.1016/j.gyobfe.2013.08.017. Epub 2014 Jan 3. French.

PMID:
24394327
42.

Concomitant resistance and early-breast cancer: should we change treatment strategies?

Galmarini CM, Tredan O, Galmarini FC.

Cancer Metastasis Rev. 2014 Mar;33(1):271-83. doi: 10.1007/s10555-013-9449-1. Review.

PMID:
24346157
43.

Trends in cancer-targeted antibody-drug conjugates.

Bidard FC, Trédan O.

Target Oncol. 2014 Mar;9(1):1-8. doi: 10.1007/s11523-013-0302-9. Epub 2013 Nov 13. Review.

PMID:
24221961
44.

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.

Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodríguez-Lescure Á, Seguí MA, Tredan O, Antón A, Ramos M, Cámara Mdel C, Rodríguez-Martín C, Carrasco E, Alba E.

Breast Cancer Res. 2013 Nov 6;15(6):R105. doi: 10.1186/bcr3572.

45.

Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study.

Touillaud M, Foucaut AM, Berthouze SE, Reynes E, Kempf-Lépine AS, Carretier J, Pérol D, Guillemaut S, Chabaud S, Bourne-Branchu V, Perrier L, Trédan O, Fervers B, Bachmann P.

BMJ Open. 2013 Oct 28;3(10):e003855. doi: 10.1136/bmjopen-2013-003855.

46.

Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial.

Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E, Stefani L, Savinelli F, Atlassi M, Salvat J, Pujade-Lauraine E, Freyer G.

Ann Oncol. 2013 Nov;24(11):2808-13. doi: 10.1093/annonc/mdt360. Epub 2013 Sep 22.

PMID:
24061628
47.

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer.

Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B, Trédan O.

Cancer Lett. 2014 Feb 1;343(1):33-41. doi: 10.1016/j.canlet.2013.09.011. Epub 2013 Sep 14.

PMID:
24041867
48.

[Physical activity and cancer survival].

Romieu I, Touillaud M, Ferrari P, Bignon YJ, Antoun S, Berthouze-Aranda S, Bachmann P, Duclos M, Ninot G, Romieu G, Sénesse P, Behrendt J, Balosso J, Pavic M, Kerbrat P, Serin D, Trédan O, Fervers B.

Bull Cancer. 2012 Oct;99(10):979-94. doi: 10.1684/bdc.2012.1648. French.

49.

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

Patel KJ, Trédan O, Tannock IF.

Cancer Chemother Pharmacol. 2013 Jul;72(1):127-38. doi: 10.1007/s00280-013-2176-z. Epub 2013 May 17.

PMID:
23680920
50.

Targeted treatments for breast cancer: a step forward.

Bachelot T, Tredan O.

Lancet Oncol. 2013 May;14(6):438-9. doi: 10.1016/S1470-2045(13)70153-0. Epub 2013 Apr 18. No abstract available.

PMID:
23602602

Supplemental Content

Loading ...
Support Center